Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03221582 · ClinicalTrials.gov registry record · Phase 4
Impact of Hepatitis C Therapy and Bone Health
A Phase 4 study, sponsored by Dallas VA Medical Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03221582 is a Phase 4 study that was terminated before completion, run by Dallas VA Medical Center. The registered enrollment target is 6 participants.
The verdict
NCT03221582, a Phase 4 study, was terminated before completion, sponsored by Dallas VA Medical Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
Interventions
- DRUG EBR/GZR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03221582
The ClinicalTrials.gov registry entry for NCT03221582 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dallas VA Medical Center, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EBR/GZR is the first listed.
NCT03221582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03221582 about?
NCT03221582 is a clinical study titled "Impact of Hepatitis C Therapy and Bone Health". An evaluation of the impact of Elbasvir and Grazoprevir (EBR/GZR) HCV therapy on the heart risk and bone health of HCV mono-infected and HIV/HCV co-infected patients.
What is the current status of trial NCT03221582?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2017-08-28. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03221582?
The interventions under investigation include: EBR/GZR (DRUG).
Who is sponsoring clinical trial NCT03221582?
This trial is sponsored by Dallas VA Medical Center, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.